Business
Pediatrix Medical Group Reports First Quarter Results
FORT LAUDERDALE, Fla., May 06, 2025--Pediatrix Medical Group Reports First Quarter Results
About this update from Pediatrix Medical Group, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":309,"url":"https://media.zenfs.com/en/business-wire.com/34ed0222036bdf86f9c957a07425030a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rz_tyhljO3DgIiSqBnHchg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYxODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/34ed0222036bdf86f9c957a07425030a","width":480,"height":309}},"lazy":false},{"type":"text","content":"Raises Full Year 2025 Adjusted EBITDA Outlook Range","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"FORT LAUDERDALE, Fla., May 06, 2025--(BUSINESS WIRE)--Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33.","length":286,"tagName":"p"},{"type":"text","content":"For the 2025 first quarter, Pediatrix reported the following results:","length":69,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenue of $458 million;","length":28,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net income of $21 million; and","length":30,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Adjusted EBITDA of $49 million.","length":31,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":89,"olType":false},{"type":"text","content":""Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong first quarter performance, we are raising our full year 2025 Adjusted EBITDA outlook from a range of $215 million to $235 million to a range of $220 million to $240 million, demonstrating our commitment to delivering value for our stakeholders," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "While we are raising our guidance, we remain mindful of the uncertainty that we face in the healthcare industry and the broad economic turbulence that is challenging virtually all companies."","length":772,"tagName":"p"},{"type":"text","content":"Operating Results– Three Months Ended Ma...